Head and neck cancer that has come back or spread
A chance for longer life
Living longer may be possible on ERBITUX with platinum-based chemotherapy and fluorouracil (CT).
If you have a certain type of head and neck cancer that has come back or spread, see how ERBITUX with CT may be able to help you.
ERBITUX (cetuximab) with platinum-based chemotherapy and fluorouracil (CT) was studied in a clinical trial of people with a certain type of head and neck cancer that had come back or spread.
This clinical study took place outside of the United States with 442 people who were diagnosed with, but not previously treated for, head and neck cancer that returned to the same location or had spread to other parts of the body. About half of the people (222) received a cetuximab product (ERBITUX*) with platinum-based chemotherapy (cisplatin or carboplatin) and fluorouracil (CT). The other half of the people (220) was treated with CT alone (platinum-based chemotherapy and fluorouracil).
The main goal of the study was to measure how long people lived overall (median overall survival). Additional goals of the study were to find out how many people had their tumors shrink or disappear (objective response rate), and to measure the length of time people lived without their cancer growing or spreading (progression-free survival).